Practical Neurology

The @US_FDA granted Breakthrough Therapy designation to VER-01, an investigational non-opioid therapy for chronic low back #pain. ow.ly/LoFN50Z1SS1 @ASRA_Society @AANmember @AmerMedicalAssn

Adjunctive treatment with #alteplase after successful #thrombectomy increased the proportion of individuals achieving excellent functional outcomes at 90 days after acute #ischemic #stroke. Results from the CHOICE-2 study published in @JAMA_current. ow.ly/W5KG50Z1SVh #Activase @genentech @American_Stroke @American_Heart @AANmember

An audit published in @TheLancet identified 4046 fabricated references across 2810 biomedical publications, with the rate of fabricated references increasing sharply from 2023 to early 2026. Read here for more details. @AmerMedicalAssn @AMA ow.ly/no7a50Z0qqE

The @US_FDA has extended its review of the supplemental biologics license application for #Leqembi #IQLIK as a subcutaneous starting dose after @EisaiUS and @Biogen submitted additional information. The new action date is August 24, 2026. @alzassociation @AANmember #Alzheimer ow.ly/Syui50Z0pZj

The label for #Vyvgart and Vyvgart Hytrulo was expanded by the @US_FDA to include treatment for adults with AChR– #gMG serotypes, such as MuSK+, LRP4+, and triple-seronegative disease. ow.ly/l3oA50YZehf @Argenxglobal @myastheniaorg @AANmember

#Asundexian added to #antiplatelet therapy reduced recurrent #ischemic #stroke after recent noncardioembolic stroke or high-risk TIA in data published in @NEJM. ow.ly/fsrl50YZepx @American_Stroke @American_Heart

The @US_FDA approved #Ocrevus (#ocrelizumab) for the treatment of pediatric patients aged ≥10 years with relapsing-remitting #MS. ow.ly/g4B850YZegf @childneurosoc @mssociety @AANmember #multiple_sclerosis @Genentech

The @US_FDA granted 510(k) clearance to the Zeta Navigation System for image-guided #neurosurgery with applications in catheter and shunt placement, #brain biopsy, and trigeminal rhizotomy. ow.ly/rRhq50YWITQ @SNS_Neurosurg @AANSNeuro #ZetaSurgical

The @amepilepsysociety has published its first-ever evidence-based guidance for treatment of infantile #epilepsy. ow.ly/Bsus50YWIVz @ChildNeuroSoc @AANmember

#Tazbentetol (@Spinogenix_Inc) an investigational once-daily oral therapy under development for the treatment of #ALS, has received @US_FDA Fast Track Designation. ow.ly/WtmV50YWIWk @alsassociation @AANmember

A prefilled auto-injector formulation of #Zilbrysq (@UCBUSA) demonstrated pharmacokinetic equivalence and high rates of successful self-administration in individuals with #generalizedMyastheniaGravis. Data presented at #AANAM 2026. ow.ly/VVt450YTz25 @AANmember #gMG

Treatment with #alixorexton (@Alkermes), an investigational oral #orexin 2 receptor agonist, was associated with improvements in disease severity, cognitive symptoms, and fatigue in adults with #narcolepsy type 1. ow.ly/KEVp50YTz6c #AANAM @AANmember @AASMorg #Sleep

A fixed-dose triple #antihypertensive pill reduced recurrent #stroke risk by ~39% vs placebo in data published in @NEJM. ow.ly/ay4750YTz8h @AANmember @American_Stroke @American_Heart

The @US_FDA has published draft guidance on the use of next-generation sequencing to assess safety of genome editing therapies. ow.ly/yxte50YTzb0 @AANmember #NeuroTwitter

Phase 3 ADAPT SERON trial shows #Vyvgart treatment significantly improved MG-ADL scores in adults with AChR-Ab-negative generalized #myasthenia gravis. Data presented at #AANAM 2026. ow.ly/T83p50YTEC2 @AANmember #efgartigimod @argenxglobal #gMG

New real-world data suggest #Fintepla may reduce #healthcare resource utilization and #antiseizure medication burden in #Lennox_Gastaut syndrome, with a 12-month persistence of 61%. ow.ly/wroe50YTzcb @UCBUSA @Amepilepsysoc @AANmember

In a prospective study published in @JAMANetwork, 25.7% of adults 60 or older maintained adequate #thyroid function after 1 year of #levothyroxine discontinuation, potentially reducing overtreatment risks such as #cognitive impairment. ow.ly/lcrq50YTzgj @AANmember

The @US_FDA has approved #Auvelity Tx for agitation associated with #Alzheimer disease #dementia—the first non-antipsychotic drug for this indication. ow.ly/p6aJ50YTzhN @AANmember @Alzassociation @axsome

Results from prospective randomized studies presented at #AANAM 2026 show that a wrist-worn #TAPS #neuromodulation device reduced #tremor in both arms for adults with #essential_tremor. ow.ly/zm2p50YPsN8 @CalaHealth @AANmember @amepilepsysoc

Higher doses of #Xywav were associated with improvements in #cognitive complaints, functional outcomes, and work productivity in individuals with #narcolepsy. Findings presented at #AANAM 2026. ow.ly/KqQs50YRuH1 @AANmember @JazzPharma